Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow TTRX by emailGet an email when TTRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TTRX, unsubscribe in one click. Privacy
📣 What TTRX Says Is Next
second quarter of 2027 · “The Company is targeting first patient enrollment in the second quarter of 2027. 2 Second Quarter 2026 Financial Results The following highlights summarize the Company’s cash position and spending for the second quarter of 2026:”
Company press release, Aug 12, 2026 · SEC filing
by the end of 2026 · “The study continued without interruption during the interim review, and the Company remains on track to complete enrollment by the end of 2026.”
Company press release, Aug 12, 2026 · SEC filing
by year-end · “The Phase 2 study continued uninterrupted, and we remain on track to complete enrollment by year-end,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics.”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full TTRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TTRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.